Lexicon Pharmaceuticals (LXRX +8.6%) is trading higher today after announcing successful...

|About: Lexicon Pharmaceuticals, Inc. (LXRX)|By:, SA News Editor

Lexicon Pharmaceuticals (LXRX +8.6%) is trading higher today after announcing successful top-line results from its first clinical study testing its combination of LX4211 and DPP-4, one of the most widely used diabetes drugs. Results showed a greater reduction in blood sugar levels after meals in type 2 diabetes patients than with just the DPP-4 inhibitor alone.